LY6D antibody (AA 21-111)

Catalog No. ABIN7872120

The Rabbit Polyclonal anti-LY6D antibody is suitable to detect LY6D in samples from Human. It has been validated for ELISA, WB and IHC.

Quick Overview for LY6D antibody (AA 21-111) (ABIN7872120)

Target: LY6D (Lymphocyte Antigen 6 Complex, Locus D (LY6D))

Reactivity: Human

Host: Rabbit

Clonality: Polyclonal

Conjugate: This LY6D antibody is un-conjugated

Application: ELISA, Western Blotting (WB), Immunohistochemistry (IHC)

Product Details anti-LY6D Antibody

Binding Specificity: AA 21-111

Purpose: LY6D Antibody / Lymphocyte antigen 6D

Purification: Immunogen affinity purified

Immunogen: E.coli-derived human LY6D recombinant protein (Position: L21-L111) was used as the immunogen for the LY6D antibody.

Isotype: IgG

Application Details

Application Notes: Optimal dilution of the LY6D antibody should be determined by the researcher.

Restrictions: For Research Use only

Handling

Format: Lyophilized

Reconstitution: Adding 0.2 mL of distilled water will yield a concentration of 500 μg/mL

Buffer: Each vial contains 4 mg Trehalose, 0.9 mg NaCl, 0.2 mg Na2HPO4.

Storage: 4 °C,-20 °C

Storage Comment: After reconstitution, the LY6D antibody can be stored for up to one month at 4oC. For long-term, aliquot and store at -20oC. Avoid repeated freezing and thawing.

Target Details for LY6D

Target: LY6D (Lymphocyte Antigen 6 Complex, Locus D (LY6D))

Alternative Name: LY6D

Background: LY6D antibody detects Lymphocyte antigen 6D, encoded by the LY6D gene. Lymphocyte antigen 6D is a glycosylphosphatidylinositol-anchored cell surface protein of the LY6/uPAR family, expressed in epithelial cells and lymphoid precursors. LY6D antibody provides researchers with a specific reagent for studying epithelial differentiation, lymphoid specification, and cancer biology.

Lymphocyte antigen 6D belongs to a family of GPI-anchored proteins characterized by the LY6/uPAR domain. Research using LY6D antibody has shown that it is expressed in epithelial cells of skin and mucosa, where it contributes to barrier formation and differentiation. In the hematopoietic system, LY6D marks early B cell precursors and distinguishes B lineage commitment from alternative lymphoid fates.

Studies with LY6D antibody have revealed that LY6D serves as a robust marker of B cell development in both mice and humans. Expression of LY6D indicates initiation of the B cell program, allowing identification of common lymphoid progenitors committed to B lineage. This makes LY6D antibody an important tool for immunology research and flow cytometric analysis of hematopoiesis.

Dysregulation of Lymphocyte antigen 6D has been associated with cancer and immune disorders. Research using LY6D antibody has shown that it is overexpressed in squamous cell carcinomas of head, neck, and esophagus, where it promotes tumor growth and invasion. In addition, LY6D has been proposed as a diagnostic biomarker and potential therapeutic target in epithelial cancers. Its expression in immune precursors also makes it relevant in studies of immune reconstitution and leukemia.

LY6D antibody is widely applied in flow cytometry, immunohistochemistry, and western blotting. Flow cytometry identifies B lineage progenitors, immunohistochemistry highlights epithelial expression in normal and tumor tissues, and western blotting quantifies levels across developmental and disease states. These applications make LY6D antibody indispensable for immunology and cancer research.

By providing validated LY6D antibody reagents, NSJ Bioreagents supports studies into epithelial differentiation, B cell biology, and cancer. Detection of Lymphocyte antigen 6D provides researchers with insight into how cell surface antigens regulate immunity and tumor progression.

UniProt: Q14210